Joe Ponzio explores Phil Fisher's second question by looking at two examples.

The 30 stocks in the Dow Jones Industrials are trading for 82% of Morningstar.com's estimated fair value, which makes the Dow an undervalued 5-star market. Eleven of the 30 industrials are undervalued 5-star stocks, according to Morningstar.

A review of the performance of the Fat Pitch Financials Portfolio for the first quarter of 2008.

Most people are staying away from pharmaceuticals and indeed, the stocks are not benefiting as much as more volatile sectors in these sudden bull rallies but we are looking for long term value and margin of safety. Most analysts are just saying hold but this could be a very good time to snap-up some shares!

I reviewed my portolio and went over why I own my current positions and why I sold positions recently.

The Fat Pitch Financials Portfolio held steady in February. I added a position in Premier Exhibitions (PRXI) and watched several positive developments in other positions. The portfolio continues to beat out the S&P 500.

A look back at the performance of the Fat Pitch Financials Portfolio. My 12.22% return was pretty respectable given that the S&P 500 delivered less than half that. This post recaps my trades and current holdings.

I review my portoflio and briefly look over some new ideas

The Fat Pitch Financials Port was up 8.35% in October and is currently up 15.19% over the past 12 months. Merck, Microsoft and Unilever were the most interesting positions this month.

Analysis of three potential healthcare values.

-Added Positions: FPFC, PFE,
-Reduced Positions: ANAT, BAC, CITZ, CMCSA, CNA, DLM, FNFG, MON, NEU, NITE, NYM, STR, T, TRV, USU,
-Sold Out: DEVC, HON,

In April, the Fat Pitch Financials Portfolio returned 5.93%. Year-to-date, the portfolio has returned 5.39%. The only major change this month was the addition of Broadridge Financial Solutions to the portfolio on April 10, 2007.

The basics of value investing through the eyes of a ten year old (and his Dad).

A Recent report by the Government Accountability Office (GAO) found that the pharmaceutical industry was in fact losing to the biotech industry in the number of new molecular entities (NMEs) approved by the FDA over the last few years.

The biotech industry has failed in its attempt to function as a science-based business